

Patient	Age/ Gender	Induction Regimen	Consolidation Regimen	Salvage Regimen
1	32M	Cytarabine/Daunorubicin	N/A (refractory)	Idarubicin/Fludarabine/ Cytarabine
2	70F	Cytarabine/Mitoxantrone	N/A (refractory)	N/A
3	29F	Cytarabine/Daunorubicin/Etoposide	Allogeneic Transplant	N/A
4	68M	Cytarabine/Mitoxantrone	Cytarabine/Mitoxantrone	N/A
5	55M	Cytarabine/Daunorubicin	N/A (refractory)	Idarubicin/Fludarabine/ Cytarabine
6	23F	Cytarabine/Dauno/Etoposide	N/A (refractory)	Mitoxantrone/ Etoposide/Cytarabine
7	61M	Cytarabine/Daunorubicin/Etoposide	N/A (refractory)	Carboplatin/Topotecan
8	72M	Cytarabine/Mitoxantrone	High dose Cytarabine	N/A
9	54F	Mitoxantrone/ Etoposide/Cytarabine	High dose Cytarabine	Clofarabine
10	64F	Cytarabine/Daunorubicin	N/A (refractory)	High dose Cytarabine
11	56M	Cytarabine/Daunorubicin	N/A (refractory)	High dose Cytarabine
12	33F	Cytarabine/Daunorubicin	High dose Cytarabine	Cytarabine/Clofarabine
13	62F	Cytarabine/Daunorubicin	N/A (refractory)	Mitoxantrone/ Etoposide/Cytarabine
14	66F	Cytarabine/Daunorubicin	N/A (refractory)	N/A

**Supplemental Table 1.** Summary of conventional treatments received prior to enrollment on quizartinib study. Cytarabine was administered by continuous infusion during induction. All 14 patients in this series had normal diploid cytogenetics at diagnosis.